Business Wire

ENOSIUM-LIFE-SCI/OTIUM

5.3.2024 10:01:27 CET | Business Wire | Press release

Share
Enosium Life Science, a New Integrated Scientific Services Group for Biopharma Companies in Europe

Dr Antoine Amer, supported by Otium Capital, announced the creation of Enosium Life Science, a group poised to redefine services in the healthcare market by acquiring and combining best-in-class life science experts in Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305557434/en/

Enosium Life Science aims to be a key advisory and scientific services provider for pharmaceuticals, biotech and medtech firms from clinical development to commercialisation. Antoine Amer brings 20+ years of global pharmaceutical leadership experience in launching and growing healthcare innovations.

A Multi-Specialist European Group Dedicated to Life Sciences

Enosium Life Science combines local knowledge, scientific expertise, entrepreneurial agility, and international standards to address critical challenges facing pharmaceutical companies.

Enosium Life Science will implement a targeted acquisition strategy, focusing on service providers in: clinical research (CRO), regulatory affairs, market access, medical affairs, and marketing, to offer an end-to-end continuum of science-based services.

Antoine Amer, Enosium Life Science CEO, commented, "Our vision is to combine the best expertise across Europe, providing a unique and comprehensive range of scientific services to address growing complexities in the European healthcare ecosystem, which will enable faster and broader access to medical innovations for patients."

François Durvye, Otium Capital CEO, added, "Investing in Enosium Life Science demonstrates our commitment to supporting innovation and excellence in this key field. Led by Antoine Amer, Enosium Life Science aims to address the major challenges in medical innovations and improving patients’ health and quality of life."

About Enosium Life Science:

Enosium Life Science is an integrated group of scientific services for the European life sciences market. Providing comprehensive expertise from clinical development to commercialisation (clinical research, regulatory affairs, market access, medical affairs, marketing), Enosium Life Science is committed to becoming the partner-of-choice for healthcare industries, and to address the critical challenges facing pharma, biotech and medtech companies.

About Otium Capital:

Otium Capital is a major player in private investment in France with €1.5 billion in assets under management. Serving as the Family Office for French entrepreneur and founder of Smartbox Pierre-Edouard Stérin, Otium Capital invests across various domains. With significant experience in healthcare (Owkin, Hapni, Okomera, etc.) and expertise in buy-and-build strategies (Otium Leisure, Novavet, Otelium, Alfeor), Otium Capital is a key player in fostering innovation and growth.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305557434/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates1.10.2026 10:30:00 CEST | Press release

The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assetsThe partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territoriesThe partnership brings together Samsung Bioepis’ development, regulatory and manufacturing capabilities with Teva’s global commercial reach to advance the investigational biosimilar candidates and help bring additional important treatment options to patients worldwide Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizum

FPT and ZEBOX Partner to Advance AI and Sustainable Innovation in Logistics1.10.2026 10:00:00 CEST | Press release

FPT, a global technology and IT services provider, and ZEBOX, the international innovation accelerator initiated by the CMA CGM Group, have entered into a three-year strategic partnership to develop and deploy AI-powered solutions for the transport and logistics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001622214/en/ The partnership was formalized during the Vietnam - France Leaders Forum, held as part of Vietnam’s General Secretary and State President’s official visit to France. The partnership will combine FPT’s expertise in artificial intelligence, automation and large-scale digital transformation with ZEBOX’s innovation network and its close connection to the CMA CGM Group’s global transport and logistics ecosystem. The partners will focus on shipping, port operations, logistics, supply chain management and clean energy. A first joint initiative in Vietnam As a first step, FPT, ZEBOX and CMA CGM Vietnam

Telekom Srbija (Group) Is Building City-Scale Digital Infrastructure for EXPO 20271.10.2026 10:00:00 CEST | Press release

On a site that will function, in terms of capacity, as an entirely new urban district, with more than 46 kilometres of fibre-optic network, 35 radio sites, 5G Standalone and Wi-Fi 7, Telekom Srbija Group is presenting the digital ecosystem it is building for over 135 participating countries and four million expected visitors. Telekom Srbija sees EXPO 2027 as a platform for strengthening its global positioning and marketing its products and services. Telekom Srbija Group is building telecommunications infrastructure at the EXPO 2027 Belgrade site whose mobile segment is comparable in scale to that of an entire urban district. On a site that previously had no telecommunications infrastructure, more than 14 kilometres of telecommunications ducting and over 46 kilometres of high-capacity fibre-optic network have been delivered so far, together with 35 advanced radio access network sites. The digital ecosystem, based on 5G Standalone and Wi-Fi 7 technologies, is designed to provide reliable

ROYC Group Launches ROYC Operating System as a Standalone Enterprise Software Platform1.10.2026 09:30:00 CEST | Press release

ROYC Group today announced the launch of ROYC Operating System (ROYC OS) as a standalone software platform for fund managers, banks and wealth managers across private markets. The software is now available separately from ROYC’s existing structuring, fund operations and distribution services. Proven in production, at scale ROYC used its structuring and fund operations experience to develop its enterprise-grade digital offering that automates these services. The technology has been live in production for years, bundled with ROYC's services with more than 20 fund managers operating drawdown and evergreen funds on the ROYC OS, distributing to over 50 banks and wealth managers. “We saw where legacy solutions were failing fund managers: spreadsheets and software assembled from separate tools bolted together over time, with no single record connecting a fund to its service providers and investors,” said Octavian Popescu, Co-Founder and CEO of ROYC Group. “We built ROYC OS the other way aroun

Eaton Strengthens European Manufacturing With Expanded Production Facility in Austria1.10.2026 09:00:00 CEST | Press release

Increased capacity supports growing demand from electrification and critical infrastructure marketsNew fully automated miniature circuit breaker production and expanded low-voltage systems assembly capacity in Schrems5,000 m² facility expansion combines advanced automation, digital integration and end-to-end product traceability Eaton will celebrate the expansion of its manufacturing facility in Schrems, Austria, on 1 October 2026. The expansion supports growing demand driven by electrification and digitalisation across Europe while increasing regional manufacturing capacity for electrical protection and power management solutions. Completed in less than ten months, the expansion combines fully automated production with advanced digital integration and end-to-end product traceability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001416101/en/ Eaton expanded manufacturing capacity in Europe for power management solutions

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye